Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | Director | June 30, 2023 | July 03, 2023 |
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Accounting Officer | July 28, 2026 | July 31, 2026 |
| Vincerx Pharma, Inc.LSAC · Entity 84409 | Director | March 05, 2020 | March 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bio Green Med Solution, Inc.
Report date June 30, 2023 · Filed July 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,602 |
Reported balance
After 2023-06-30 transaction · row 1
1 source rowRow 1 · 2023-06-30 · Grant · Acquired 21,219 · Balance 40,602 F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-06-30 | Direct | 42,438 |
Reported balance
After 2023-06-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-30 · Grant · Acquired 42,438 · Balance 42,438 F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024.
F2: These securities were granted to Ms. Walker for her services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 10,000 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 15,000 · Balance 25,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 15,000 · Balance 10,000 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 25,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 25,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 25,000 RSUs reported in Table I (10,000 RSUs) are subject to vesting.
Vincerx Pharma, Inc.
Report date March 05, 2020 · Filed March 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,000 |
Reported balance
Holding disclosure · report date 2020-03-05 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 6,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2017 Filed Sep 29, 2017 21:16 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 1,500 | $27.81 | $41,715.00 |
DisclosureSEC source: 0000899243-17-022968 · doc4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option(right to buy) · Derivative | 5,000 | $0.00 Strike: $9.75 | $0.00 |
DisclosureSEC source: 0000899243-17-018551 · doc4.xml · derivative · entry 4 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 5,000 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on May 20, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 3,600 | $65.21 | $234,754.92 |
DisclosureSEC source: 0000899243-17-018551 · doc4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $64.69 to $65.63, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,400 | $64.06 | $89,684.56 |
DisclosureSEC source: 0000899243-17-018551 · doc4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,600 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $63.65 to $64.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 17, 2017 Filed Jul 19, 2017 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $9.75 | $48,750.00 |
DisclosureSEC source: 0000899243-17-018551 · doc4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $29.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010521 · doc4.xml · derivative · entry 7 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Ordinary Shares · 2,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 4, 2015 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.75 | $0.00 |
DisclosureSEC source: 0000899243-17-010521 · doc4.xml · derivative · entry 6 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 3,000 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on May 20, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,000 | $52.29 | $104,581.60 |
DisclosureSEC source: 0000899243-17-010521 · doc4.xml · nonDerivative · entry 5 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $51.68 to $52.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,000 | $29.81 | $59,620.00 |
DisclosureSEC source: 0000899243-17-010521 · doc4.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 100 | $52.70 | $5,270.00 |
DisclosureSEC source: 0000899243-17-010521 · doc4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,900 | $52.21 | $151,410.45 |
DisclosureSEC source: 0000899243-17-010521 · doc4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $51.68 to $52.64, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 17, 2017 Filed Apr 19, 2017 20:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 3,000 | $9.75 | $29,250.00 |
DisclosureSEC source: 0000899243-17-010521 · doc4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $55.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005218 · doc4.xml · derivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 22, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $29.81 | $0.00 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · derivative · entry 8 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 2,000 shares Expires 2024-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 4, 2015 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.75 | $0.00 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · derivative · entry 7 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 3,000 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on May 20, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 900 | $54.71 | $49,241.97 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · nonDerivative · entry 6 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $54.40 to $54.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,100 | $53.61 | $58,969.02 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · nonDerivative · entry 5 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $53.26 to $54.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 2,000 | $29.81 | $59,620.00 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,800 | $54.74 | $98,526.42 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $54.49 to $55.00, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 1,200 | $53.70 | $64,435.56 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $53.26 to $54.22, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| October 13, 2016 Filed Oct 14, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 3,000 | $9.75 | $29,250.00 |
DisclosureSEC source: 0000899243-16-031699 · doc4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $27.81 | $0.00 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · derivative · entry 8 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Ordinary Shares · 5,000 shares Expires 2025-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on March 11, 2016 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (right to buy) · Derivative | 7,000 | $0.00 Strike: $9.75 | $0.00 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · derivative · entry 7 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Ordinary Shares · 7,000 shares Expires 2023-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on May 20, 2014 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,500 | $61.83 | $278,253.90 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · nonDerivative · entry 6 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F5 · price: The transaction was executed in multiple trades in prices ranging from $61.79 to $61.885, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 500 | $60.01 | $30,005.00 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · nonDerivative · entry 5 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F4 · price: The transaction was executed in multiple trades in prices ranging from $60.00 to $60.025, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 5,000 | $27.81 | $139,050.00 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · nonDerivative · entry 4 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 2,700 | $61.83 | $166,942.35 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · nonDerivative · entry 3 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F3 · price: The transaction was executed in multiple trades in prices ranging from $61.79 to $61.885, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 4,300 | $60.00 | $258,002.58 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · nonDerivative · entry 2 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,700 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $60.00 to $60.025, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2016 Filed Sep 21, 2016 20:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 7,000 | $9.75 | $68,250.00 |
DisclosureSEC source: 0000899243-16-029584 · doc4.xml · nonDerivative · entry 1 Walker Karin L · CIK 0001559422 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.